Jared Kaltwasser

The 5-year survival rate over the time period was just 33.8%, the study found.

The report is based on a series of 10 cases and a literature review involving 14 cases.

The authors of a new study say patients with certain mutations appear to respond to zanubrutinib, which had a favorable safety profile.

A new report shows better than 80% concordance between liquid biopsy and tissue biopsy.

Chronic kidney disease (CKD) and diabetes were associated with a higher risk of neurocognitive decline, but kidney disease stage did not appear to affect risk.

Investigators also studied omega-6, but they found no evidence that it is involved in causing systemic lupus erythematosus (SLE).

Advances in whole genome sequencing are helpful in linking genetic variants with diseases, but the process is more challenging in cases of rare and ultra-rare diseases.

Existing research appears to suggest these patients can be treated similarly to patients with other genetic subtypes of cutaneous melanomas.

Approaches such as new types of monoclonal antibodies and chimeric antigen receptor natural killer cells could change how chronic lymphocytic leukemia is treated, according to a recent review article.

The mortality rate for patients with systemic lupus erythematosus (SLE) was greater than one-third if they were admitted to an intensive care unit (ICU).

The meta-analysis found insufficient evidence to assess the validity of the screening in diagnosing age-related macular degeneration.

About 15% of cases of large granular lymphocytic leukemia involve natural killer cells.

A new review article outlines the latest research and results into programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

The QRISK3 model outperformed more traditional models like the Framingham Risk Score, according to a new report.

Investigators sought to show how individual cases could be clarified through the use of flow cytometry analysis.

Drugs targeting pulmonary arterial hypertension often do not have clinical or functional benefits, a meta-analysis shows, for patients with comorbid pulmonary (PH) hypertension/chronic obstructive pulmonary disease (COPD).

The results of a new longitudinal analysis cast doubt on the utility of serial interferon assessment.

The data largely align with outcomes in high-income countries, with male sex and people with low body weight at particular high risk of mortality.

Measures of metabolism and energy expenditure did not appear to be associated with brown adipose tissue activation in patients with emphysematous chronic obstructive pulmonary disease (COPD).

Patients with histories of inflammatory bowel disease and systemic lupus erythematosus were also at elevated risks of myelodysplastic syndromes (MDS), the authors found.

The circulating RNA hsa_circ_0003416 appears to be downregulated in patients with pulmonary arterial hypertension (PAH), according to new research.

New subsets of patients with systemic lupus erythematosus (SLE) and new therapeutic targets have been discovered in recent years.

Many patients with chronic obstructive pulmonary disease (COPD) do not believe their cases warrant emergency department care.

This new study from Spain investigated risk factors for COPD among individuals without a smoking history.

Immunoglobulins, free light chains, and beta-2 microglobulin all show promise in tracking systemic lupus erythematosus (SLE) and other autoimmune diseases.

Patients with high eosinophil counts appeared to benefit from inhaled corticosteroid (ICS) therapy for chronic obstructive pulmonary disease (COPD), while those with low counts did not.

High-risk patients and patients with a history of pulmonary arterial hypertension (PAH) had significantly different cytokine profiles compared with patients with a low risk of the condition.

Several potential biomarkers have emerged, although most still require significant validation before they can be used in the clinic.

However, the differences did not translate into an increased or decreased death rate among the cohort.

A range of new non-serum biomarkers have been identified in recent years, but the authors of a new review urge caution until those markers are further validated.